<DOC>
	<DOCNO>NCT01571219</DOCNO>
	<brief_summary>CT-P13 ( Infliximab ) monoclonal antibody currently develop CELLTRION , Inc . This open-label , single-arm , multicenter , multiple single dose intravenous ( IV ) infusion , efficacy , safety extension study Phase 3 Study CT-P13 3.1 design assess long-term efficacy safety multiple dose CT-P13 .</brief_summary>
	<brief_title>An Extension Study Demonstrate Long-Term Efficacy Safety CT-P13 When Co-administered With Methotrexate Patient With Rheumatoid Arthritis Who Were Treated With Infliximab ( Remicade CT-P13 ) Study CT-P13 3.1</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patient complete scheduled visit , include EndofStudy Visit , Study CTP13 3.1 Patient major protocol violation Study CTP13 3.1 Patient permit enter extension study , option general practitioner investigator , patient continue gain benefit treatment extension study . Local guideline patient treatment follow Patient withdrawn Study CTP13 3.1 reason Patient , time provide informed consent , ongoing medical issue serious adverse event ( SAEs ) intolerance issue mean continuation extension study could detrimental health , opinion investigator Patient plan participate study investigational drug period extension study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>RA</keyword>
	<keyword>Biosimilar</keyword>
</DOC>